NCT01843075 (ELAD) is a Phase 2 clinical trial of Liraglutide in Alzheimer's Disease, sponsored by Imperial College London.

Who is sponsoring NCT01843075?

NCT01843075 is sponsored by Imperial College London.

What drugs are being tested in NCT01843075?

Interventions in NCT01843075: Liraglutide, Placebo.

What condition does NCT01843075 study?

NCT01843075 studies Alzheimer's Disease.

Is NCT01843075 still recruiting?

NCT01843075 is currently status unknown. Last updated 6 June 2019.

Last reviewed 2019-06-06 · How we verify

NCT01843075: ELAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)

Status unknown Phase 2 Last updated 6 June 2019

What this trial tests

Phase 2 trial testing Liraglutide in Alzheimer's Disease in 204 participants. Status unknown.

Timeline

1 January 2014

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Imperial College London
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	204
Start date	1 January 2014
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
Placebo

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Imperial College London

Who can join

50 and older, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The change in cerebral glucose metabolic rate
Time frame: 12 months
The change in cerebral glucose metabolic rate from baseline to follow up (12 months) in the treatment group compared with the placebo group.

Sponsor's own description

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.
Kellar D, Craft S. · · 2020 · cited 604× · PMID 32730766 · DOI 10.1016/s1474-4422(20)30231-3
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression.
van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, et al · · 2020 · cited 501× · PMID 32135131 · DOI 10.1016/s2213-8587(19)30405-x
Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
BDNF mediates adaptive brain and body responses to energetic challenges.
Marosi K, Mattson MP. · · 2014 · cited 412× · PMID 24361004 · DOI 10.1016/j.tem.2013.10.006
Alzheimer's disease drug development pipeline: 2018.
Cummings J, Lee G, Ritter A, Zhong K. · · 2018 · cited 402× · PMID 29955663 · DOI 10.1016/j.trci.2018.03.009
Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.
Cummings JL, Tong G, Ballard C. · · 2019 · cited 371× · PMID 30689575 · DOI 10.3233/jad-180766
Diabetes and Cognitive Impairment.
Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. · · 2016 · cited 360× · PMID 27491830 · DOI 10.1007/s11892-016-0775-x
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01843075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 6 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01843075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing